When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Leprosy

Last reviewed: 22 Nov 2024
Last updated: 10 Nov 2022

Summary

Definition

History and exam

Key diagnostic factors

  • typical skin lesions
  • nerve involvement
  • sensory loss
Full details

Other diagnostic factors

  • immunologic reactions
  • eye lesions
Full details

Risk factors

  • close contact with a person with multibacillary leprosy
  • poverty
  • residence in endemic area
  • genetic predisposition
  • zoonotic transmission
Full details

Diagnostic tests

1st tests to order

  • skin smear
  • skin and/or nerve biopsy and histopathology
Full details

Tests to consider

  • polymerase chain reaction
Full details

Treatment algorithm

ACUTE

multibacillary (MB) or paucibacillary (PB): no rifampin or fluoroquinolone resistance

multibacillary (MB) or paucibacillary (PB): rifampin ± fluoroquinolone resistance

ONGOING

type 1 reaction (reversal reaction)

type 2 reaction (erythema nodosum leprosum)

Lucio phenomenon

Contributors

Authors

Maria T. Ochoa, MD

Clinical Professor of Dermatology

USC Keck School of Medicine

Department of Dermatology

Los Angeles

CA

Disclosures

MTO declares that she has no competing interests.

Acknowledgements

Dr Maria T. Ochoa would like to gratefully acknowledge Dr Denis Paul Jacques Daumerie, a previous contributor to this topic. DPJD declares that he has no competing interests.

Peer reviewers

Hubert Sansarricq, MD

Member of World Health Organization Panel of Experts on Leprosy

Saint-Armour Morlaas

France

Disclosures

HS declares that he has no competing interests.

David M. Scollard, MD, PhD

Chief

Clinical Branch

National Hansen's Disease Programs

Baton Rouge

LA

Disclosures

DMS declares that he has no competing interests.

Alexandre Tiendrebéogo, MD, MPH

Medical Officer

Leprosy and Neglected Tropical Diseases in Central Africa Countries

World Health Organization

Country Office of Kinshasa

DR of Congo

Disclosures

AT declares that he has no competing interests.

  • Leprosy images
  • Differentials

    • Psoriasis
    • Eczema
    • Tinea corporis
    More Differentials
  • Guidelines

    • Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021-2030
    • Leprosy/Hansen disease: contact tracing and post-exposure prophylaxis
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer